H-100 is under clinical development by Petros Pharmaceuticals and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect H-100’s likelihood of approval (LoA) and phase transition for Peyronies Disease took place on 18 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their H-100 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

H-100 overview

H-100 is under development for the treatment of Peyronie's disease. The drug candidate is applied topically. It is developed based on the company's advancement in the area of sub-dermal treatment delivery.

Petros Pharmaceuticals overview

Petros Pharmaceuticals is a men’s health pharmaceutical company. The company is headquartered in Washington DC, the US.

Quick View H-100 LOA Data

Report Segments
  • Innovator
Drug Name
  • H-100
Administration Pathway
  • Topical
Therapeutic Areas
  • Male Health
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.